-
Abedon ST (2018) Bacteriophage-mediated biocontrol of wound infections, and ecological exploitation of biofilms by phages. In: Shiffman MA, Low M (eds) Recent clinical techniques, results, and research in wounds. Springer, Berlin, pp 1-38
-
Abedon ST, Garcia P, Mullany P, Aminov R, 2017: Editorial: phage therapy: past, present and future[J]. Front Microbiol, 8, 981-. doi: 10.3389/fmicb.2017.00981
-
Akanda ZZ, Taha M, Abdelbary H, 2018: Current review-The rise of bacteriophage as a unique therapeutic platform in treating peri-prosthetic joint infections[J]. J Orthop Res, 36, 1051-1060.
-
Bai J, Jeon B, Ryu S, 2019: Effective inhibition of Salmonella typhimurium in fresh produce by a phage cocktail targeting multiple host receptors[J]. Food Microbiol, 77, 52-60. doi: 10.1016/j.fm.2018.08.011
-
Borysowski J, Weber-Dąbrowska B, Górski A, 2006: Bacteriophage endolysins as a novel class of antibacterial agents[J]. Exp Biol Med (Maywood), 231, 366-377. doi: 10.1177/153537020623100402
-
Borysowski J, Lobocka M, Międzybrodzki R, Weber-Dąbrowska B, Górski A, 2011: Potential of bacteriophages and their lysins in the treatment of MRSA: current status and future perspectives[J]. BioDrugs, 25, 347-355. doi: 10.2165/11595610-000000000-00000
-
Chan BK, Abedon ST, 2015: Bacteriophages and their enzymes in biofilm control[J]. Curr Pharm Des, 21, 85-99.
-
Chaudhry WN, Concepción-Acevedo J, Park T, Andleeb S, Bull JJ, Levin BR, 2017: Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms[J]. PLoS ONE, 12, e0168615-. doi: 10.1371/journal.pone.0168615
-
Chopra S, Harjai K, Chhibber S, 2015: Potential of sequential treatment with minocycline and S. aureus specific phage lysin in eradication of MRSA biofilms: an in vitro study[J]. Appl Microbiol Biotechnol, 99, 3201-3210. doi: 10.1007/s00253-015-6460-1
-
Fischetti VA, 2017: Lysin therapy for Staphylococcus aureus and other bacterial pathogens[J]. Curr Top Microbiol Immunol, 409, 529-540.
-
Fischetti VA, 2018: Development of phage lysins as novel therapeutics: a historical perspective[J]. Viruses, 10, E310-. doi: 10.3390/v10060310
-
Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM, 2010: Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system[J]. Antimicrob Agents Chemother, 54, 397-404. doi: 10.1128/AAC.00669-09
-
Górski A, Międzybrodzki R, Węgrzyn G, Jończyk-Matysiak E, Borysowski J, Weber-Dąbrowska B (2019) Phage therapy: current status and perspectives. Med Res Rev. https: //doi.org/10.1002/med.21593
-
Gray JA, Chandry PS, Kaur M, Kocharunchitt C, Bowman JP, Fox EM, 2018: Novel biocontrol methods for Listeria monocytogenes biofilms in food production facilities[J]. Front Microbiol, 9, 605-. doi: 10.3389/fmicb.2018.00605
-
Guo M, Feng C, Ren J, Zhuang X, Zhang Y, Zhu Y, Dong K, He P, Guo X, Qin J, 2017: A novel antimicrobial endolysin, LysPA26, against Pseudomonas aeruginosa[J]. Front Microbiol, 8, 293-.
-
Henriksen K, RØrbo N, Rybtke ML, Martinet MG, Tolker-Nielsen T, Høiby N, Middelboe M, Ciofu O, 2019: P. aeruginosa flow-cell biofilms are enhanced by repeating phage treatments but can be eradicated by phage-ciprofloxacin combination[J]. Pathog Dis, 77, ftz011-.
-
Hesse S, Adhya S, 2019: Phage therapy in the twenty-first century: facing the decline of the antibiotic era; is it finally time for the age of the phage[J]. Annu Rev Microbiol, 73, 155-174. doi: 10.1146/annurev-micro-090817-062535
-
Issa R, Chanishvili N, Caplin J, Kakabadze E, Bakuradze N, Makalatia K, Cooper I, 2019: Anti-biofilm potential of purified environmental bacteriophage preparations against early stage Pseudomonas aeruginosa biofilms[J]. J Appl Microbiol, 126, 1657-1667. doi: 10.1111/jam.14241
-
Kaur S, Harjai K, Chhibber S, 2016: In vivo assessment of phage and linezolid based implant coating for treatment of Methicillin Resistant S. aureus (MRSA) mediated orthopaedic device related infections[J]. PLoS ONE, 11, e0157626-. doi: 10.1371/journal.pone.0157626
-
Khalifa L, Brosh Y, Gelman D, Coppenhagen-Glazer S, Beyth S, Poradosu-Cohen R, Que YA, Beyth N, Hazan R, 2015: Targeting Enterococcus faecalis biofilms with phage therapy[J]. Appl Environ Microbiol, 81, 2696-2705. doi: 10.1128/AEM.00096-15
-
Khalifa L, Shlezinger M, Beyth S, Houri-Haddad Y, Coppenhagen-Glazer S, Beyth N, Hazan R, 2016: Phage therapy against Enterococcus faecalis in dental root canals[J]. J Oral Microbiol, 8, 32157-. doi: 10.3402/jom.v8.32157
-
Kropinski AM, 2006: Phage therapy—everything old is new again[J]. Can J Infect Dis Med Microbiol, 17, 297-306. doi: 10.1155/2006/329465
-
Kumaran D, Taha M, Yi Q, Ramirez-Arcos S, Diallo JS, Carli A, Abdelbary H, 2018: Does treatment order matter? Investigating the ability of bacteriophage to augment antibiotic activity against Staphylococcus aureus biofilms[J]. Front Microbiol, 9, 127-. doi: 10.3389/fmicb.2018.00127
-
Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, Schuch R, Fischetti VA, 2015: Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model[J]. Antimicrob Agents Chemother, 59, 1983-1991. doi: 10.1128/AAC.04641-14
-
Mah TF, O'Toole GA, 2001: Mechanisms of biofilm resistance to antimicrobial agents[J]. Trends Microbiol, 9, 34-39. doi: 10.1016/S0966-842X(00)01913-2
-
Malik S, Sidhu PK, Rana JS, Nehra K (2019) Managing urinary tract infections through phage therapy: a novel approach. Folia Microbiol (Praha) Sep 7. https: //doi.org/10.1007/s12223-019-00750-y
-
Maszewska A, Zygmunt M, Grzejdziak I, Różalski A, 2018: Use of polyvalent bacteriophages to combat biofilm of Proteus mirabilis causing catheter-associated urinary tract infections[J]. J Appl Microbiol, 125, 1253-1265. doi: 10.1111/jam.14026
-
McCallin S, Sacher JC, Zheng J, Chan BK, 2019: Current state of compassionate phage therapy[J]. Viruses, 11, E343-. doi: 10.3390/v11040343
-
Melo LD, Veiga P, Cerca N, Kropinski AM, Almeida C, Azeredo J, Sillankorva S, 2016: Development of a phage cocktail to control Proteus mirabilis catheter-associated urinary tract infections[J]. Front Microbiol, 7, 1024-.
-
Melo LDR, Brandao A, Akturk E, Santos SB, Azeredo J, 2018: Characterization of a new Staphylococcus aureus Kayvirus harboring a lysin active against biofilms[J]. Viruses, 10, E182-. doi: 10.3390/v10040182
-
Melo LDR, Pires DP, Monteiro R, Azeredo J (2019) Phage therapy of infectious biofilms: challenges and strategies. In: Górski A, Międzybrodzki R, Borysowski J (eds) Phage therapy: a Practical approach. Springer, Switzerland, pp 295-313
-
Morris J, Kelly N, Elliot L, Grant A, Wilkinson M, Hazratwala K, McEwen P, 2019: Evaluation of bacteriophage anti-biofilm activity for potential control of orthopedic implant-related infections caused by Staphylococcus aureus[J]. Surg Infect (Larchmt), 20, 16-24. doi: 10.1089/sur.2018.135
-
Nale JY, Chutia M, Carr P, Hickenbotham PT, Clokie M, 2016: 'Get in early'; Biofilm and wax moth (Galleria mellonella) models reveal new insights into the therapeutic potential of Clostridium difficile bacteriophages[J]. Front Microbiol, 7, 1383-.
-
Oechslin F, 2018: Resistance development to bacteriophages occurring during bacteriophage therapy[J]. Viruses, 10, 351-. doi: 10.3390/v10070351
-
Pinto G, Silva MD, Peddey M, Sillankorva S, Azeredo J, 2016: The role of bacteriophages in periodontal health and disease[J]. Future Microbiol, 11, 1359-1369. doi: 10.2217/fmb-2016-0081
-
Pires DP, Dötsch A, Anderson EM, Hao Y, Khursigara CM, Lam JS, Sillankorva S, Azeredo J, 2017a: A genotyping analysis of five P. aeruginosa strains after biofilm infection by phages targeting different cell surface receptors[J]. Front Microbiol, 8, 1229-. doi: 10.3389/fmicb.2017.01229
-
Pires DP, Melo LDR, Vilas Boas D, Sillankorva S, Azeredo J, 2017b: Phage therapy as an alternative or complementary strategy to prevent and control biofilm-related infections[J]. Curr Opin Microbiol, 39, 48-56. doi: 10.1016/j.mib.2017.09.004
-
Poonacha N, Nair S, Desai S, Tuppad D, Hiremath D, Mohan T, Vipra A, Sharma U, 2017: Efficient killing of planktonic and biofilm-embedded coagulase-negative staphylococci by bactericidal protein P128[J]. Antimicrob Agents Chemother, 61, e00457-17.
-
Ryan EM, Alkawareek MY, Donnelly RF, Gilmore BF, 2012: Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro[J]. FEMS Immunol Med Microbiol, 65, 395-398. doi: 10.1111/j.1574-695X.2012.00977.x
-
Sass P, Bierbaum G, 2007: Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus[J]. Appl Environ Microbiol, 73, 347-352. doi: 10.1128/AEM.01616-06
-
Schuch R, Khan BK, Raz A, Rotolo JA, Wittekind M, 2017: Bacteriophage lysin CF-301, a potent antistaphyloccocal biofilm agent[J]. Antimicrob Agents Chemother, 61, e02666-16.
-
Sharma U, Vipra A, Channabasappa S, 2018: Phage-derived lysins as potential agents for eradication biofilms and persisters[J]. Drug Discov Today, 23, 848-856. doi: 10.1016/j.drudis.2018.01.026
-
Sillankorva S, Azeredo J (2014) The use of bacteriophages and bacteriophage-derived enzymes for clinically relevant biofilm control. In: Borysowski J, Międzybrodzki R, Górski A (eds) Phage therapy: current research and application. Caister Academic Press, Wymondham (chapter 13)
-
Simmons M, Morales CA, Oakley BB, Seal BS, 2012: Recombinant expression of a putative amidase cloned from the genome of Listeria monocytogenes that lyses the bacterium and its monolayer in conjunction with a protease[J]. Probiotics Antimicrob Proteins, 4, 1-10.
-
Singh PK, Donovan DM, Kumar A, 2014: Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from Staphylococcus aureus endophthalmitis[J]. Antimicrob Agents Chemother, 58, 4621-4629. doi: 10.1128/AAC.00126-14
-
Szafrański SP, Winkel A, Stiesch M, 2017: The use of bacteriophages to biocontrol oral biofilms[J]. J Biotechnol, 250, 29-44. doi: 10.1016/j.jbiotec.2017.01.002
-
Taha M, Abdelbary H, Ross FP, Carli AV, 2018: New innovations in the treatment of PJI and biofilms-clinical and preclinical topics[J]. Curr Rev Musculoskelet Med, 11, 380-388. doi: 10.1007/s12178-018-9500-5
-
Thandar M, Lood R, Winer BY, Deutsch DR, Euler CW, Fischetti VA, 2016: Novel engineered peptides of a phage lysin as effective antimicrobials against multidrug-resistant Acinetobacter baumanii[J]. Antimicrob Agents Chemother, 60, 2671-2679. doi: 10.1128/AAC.02972-15
-
Tkhilaishvili T, Lombardi L, Klatt AB, Trampuz A, Di Luca M, 2018: Bacteriophage Sb-1 enhances antibiotic activity against biofilm, degrades exopolysaccharide matrix and targets persisters of Staphylococcus aureus[J]. Int J Antimicrob Agents, 52, 842-853. doi: 10.1016/j.ijantimicag.2018.09.006
-
Yang H, Yu J, Wei H, 2014: Engineered bacteriophage lysins as novel anti-infectives[J]. Front Microbiol, 5, 542-.
-
Yilmaz C, Colak M, Yilmaz BC, Ersoz G, Kutatelidze M, Gozlugol M, 2013: Bacteriophage therapy in implant-related infections: an experimental study[J]. J Bone Joint Surg Am, 95, 117-125. doi: 10.2106/JBJS.K.01135